Inmed Pharmaceuticals earnings were -$8.2M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. The latest INM earnings report on Jun 30, 2025 announced Q2 2025 earnings of -$1.8M, down 15.7% from last quarter. For the last reported fiscal year 2025 ending Jun 30, 2025, INM reported annual earnings of -$8.2M, with 6.3% growth.
Inmed Pharmaceuticals Earnings Reports & History FAQ
What were Inmed Pharmaceuticals's earnings last quarter?
On INM's earnings call on Invalid Date, Inmed Pharmaceuticals (NASDAQ: INM) reported Q2 2025 earnings per share (EPS) of -$0.43, up 88.25% year over year. Total INM earnings for the quarter were -$1.79 million. In the same quarter last year, Inmed Pharmaceuticals's earnings per share (EPS) was -$3.66.
Is Inmed Pharmaceuticals profitable or losing money?
As of the last Inmed Pharmaceuticals earnings report, Inmed Pharmaceuticals is currently losing money. Inmed Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2025 was -$8.16 million, a 6.34% increase year over year.
What was INM's earnings growth in the past year?
As of Inmed Pharmaceuticals's earnings date in Invalid Date, Inmed Pharmaceuticals's earnings has grown year over year. INM earnings in the past year totalled -$8.16 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.